Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema

The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.

Inclusion Criteria:

• Clinically diagnosed super-infected or impetiginized eczema

Exclusion Criteria:

• Patients who have general signs of systemic infections like fever, malaise, lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment

• Patients who have a bacterial skin infection which, due to depth and severity, could not be appropriately treated with a topical antimicrobial or antiseptic medication

• Diagnose of the following disease:

  • Known active tuberculosis or any history of past tuberculosis of skin
  • Suspected or proven parasitic infection of the treatment site (e.g. scabies)
  • Psoriasis
  • Suspected or proven viral infection of skin (e.g. Herpes)

• Localization of the superficial infected eczema:

  • Palms of the hands
  • Sole of a foot
  • Face

• Have received any topical treatment with antibiotics, antimycotics, immunomodulators and corticosteroid preparations within the last 2 weeks before treatment with IMP